Takahiro Eitsuka

Dr. Takahiro Eitsuka


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TETakahiro Eitsuka
Takahiro Eitsuka
NTNaoto Tatewaki
Naoto Tatewaki
HNHiroshi Nishida
Hiroshi Nishida
TKTadao Kurata
Tadao Kurata
KNKiyotaka Nakagawa
Kiyotaka Nakagawa
TMTeruo Miyazawa
Teruo Miyazawa


Verified
Journal Article
Open access
PDF file
TETakahiro Eitsuka
Takahiro Eitsuka
NTNaoto Tatewaki
Naoto Tatewaki
HNHiroshi Nishida
Hiroshi Nishida
KNKiyotaka Nakagawa
Kiyotaka Nakagawa
TMTeruo Miyazawa
Teruo Miyazawa
Tocotrienol (T3), unsaturated vitamin E, is gaining a lot of attention owing to its potent anticancer effect, since its efficacy is much greater than that of tocopherol (Toc). Various factors are known to be involved in such antitumor action, including cell cycle arrest, apoptosis induction, antiangiogenesis, anti-metastasis, nuclear factor-κB suppression, and telomerase inhibition. Owing to a difference in the affinity of T3 and Toc for the α-tocopherol transfer protein, the bioavailability of orally ingested T3 is lower than that of Toc. Furthermore, cellular uptake of T3 is interrupted by coadministration of α-Toc in vitro and in vivo. Based on this, several studies are in progress to screen for molecules that can synergize with T3 in order to augment its potency. Combinations of T3 with chemotherapeutic drugs (e.g., statins, celecoxib, and gefitinib) or dietary components (e.g., polyphenols, sesamin, and ferulic acid) exhibit synergistic actions on cancer cell growth and signaling pathways. In this review, we summarize the current status of synergistic effects of T3 and an array of agents on cancer cells, and discuss their molecular mechanisms of action. These combination strategies would encourage further investigation and application in cancer prevention and therapy.

27 June 2012 in FEBS Letters
Verified
Journal Article
Open access
PDF file
TETakahiro Eitsuka
Takahiro Eitsuka
KNKiyotaka Nakagawa
Kiyotaka Nakagawa
YOYuichi Ono
Yuichi Ono
NTNaoto Tatewaki
Naoto Tatewaki
HNHiroshi Nishida
Hiroshi Nishida
TMTeruo Miyazawa
Teruo Miyazawa
Several lines of experimental data have highlighted a key role of Amadori‐glycated phosphatidylethanolamine (Amadori‐PE) in the development of diabetic complications. Recent epidemiological studies suggest that diabetes mellitus could be a risk factor for some cancers. A characteristic of cancer cells is their immortal phenotype, and the enzyme telomerase contributes to the infinite replicative potential of cancer cells. The purpose of this study was to obtain new information about the effect of Amadori‐PE on the regulation of telomerase in PANC‐1 human pancreatic carcinoma cells. Amadori‐PE enhanced cellular telomerase in a time‐ and dose‐dependent manner by up‐regulating hTERT expression through induction of c‐myc. These results provide experimental evidence for a novel role of Amadori‐PE in linking diabetes and cancer.

3 January 2017 in Journal of Cellular Biochemistry
Verified
Journal Article
Open access
PDF file
TFTomokazu Fukuda
Tomokazu Fukuda
TTTetsuya Tani
Tetsuya Tani
SHSeiki Haraguchi
Seiki Haraguchi
KDKenichiro Donai
Kenichiro Donai
NNNobuyoshi Nakajima
Nobuyoshi Nakajima
AHArata Honda
Arata Honda
Cover: The cover image, by Tomokazu Fukuda et al., is based on the Article Expression of Six Proteins Causes Reprogramming of Porcine Fibroblasts Into Induced Pluripotent Stem Cells With Both Active X Chromosomes, DOI: 10.1002/jcb.25727.